[Multicenter clinical trial of the antitumor drug Dioxadet (phase II)].
A stage II of the joint clinical study of Dioxadet, an ethylene imine drug, was carried out to evaluate its therapeutic effect in 229 patients and side-effects in 239 patients with malignancies of various sites. Marked therapeutic effect was observed in ascitic malignancies of the ovary and a moderate one--in disseminated breast cancer. The most frequent side-effect was reversible myelodepression, often delayed.